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Abstract: Recessive HACE1 mutations are associated with a severe neurodevelopmental disorder
(OMIM: 616756). However, the physiopathologycal bases of the disease are yet to be completely
clarified. Whole-exome sequencing identified homozygous HACE1 mutations (c.240C>A, p.Cys80Ter)
in a patient with brain atrophy, psychomotor retardation and 3-methylglutaconic aciduria, a biomarker
of mitochondrial dysfunction. To elucidate the pathomechanisms underlying HACE1 deficiency,
a comprehensive molecular analysis was performed in patient fibroblasts. Western Blot demonstrated
the deleterious effect of the mutation, as the complete absence of HACE1 protein was observed.
Immunofluorescence studies showed an increased number of LC3 puncta together with the normal
initiation of the autophagic cascade, indicating a reduction in the autophagic flux. Oxidative stress
response was also impaired in HACE1 fibroblasts, as shown by the reduced NQO1 and Hmox1
mRNA levels observed in H2O2-treated cells. High levels of lipid peroxidation, consistent with
accumulated oxidative damage, were also detected. Although the patient phenotype could resemble
a mitochondrial defect, the analysis of the mitochondrial function showed no major abnormalities.
However, an important increase in mitochondrial oxidative stress markers and a strong reduction in
the mitophagic flux were observed, suggesting that the recycling of damaged mitochondria might
be targeted in HACE1 cells. In summary, we demonstrate for the first time that the impairment of
autophagy, mitophagy and oxidative damage response might be involved in the pathogenesis of
HACE1 deficiency.
Keywords: HACE1; genetic disorder; autophagy; mitophagy; mitochondria; 3-methylglutaconic;
oxidative stress
1. Introduction
HACE1 (MIM#610876) encodes for a HECT domain and ankyrin repeat-containing ubiquitin
ligase which is reported to be involved in tagging specific target proteins for subcellular localization or
for degradation [1]. In addition, this protein is a potential tumor suppressor, as it has been shown to be
downregulated in many human tumors [2,3]. In addition, studies performed in cellular and mouse
models demonstrated that HACE1 is potentially involved in other physiological processes, including
the regulation of the response to oxidative stress [4–6] and autophagy [7,8].
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Recessive mutations in HACE1 causing loss-of-function have been associated to a severe genetic
neurodevelopmental disorder classified as spastic paraplegia and psychomotor retardation with or
without seizures (SPPRS) (OMIM: 616756) [9]. Affected individuals presented, in the first months of
life or infancy, with a variety of clinical symptoms, including delayed psychomotor development,
intellectual disability, epilepsy, hypotonia, spasticity, ataxia, and poor speech skills. Brain abnormalities
are also present in some patients and include hypoplastic corpus callosum, cerebral atrophy, delayed
myelination and reduced white matter content. Although mutations in HACE1 have been reported in
18 patients from eight unrelated families, the molecular mechanism underlying the pathogenesis of the
disease has not been well determined [10–13]. In fact, a very recent manuscript reported the unique
evidence to date about the pathogenic mechanisms underlying this disorder [13]. This research showed
that elevated levels of the Ras-related C3 botulinum toxin substrate 1 protein (RAC1), a well-known
target of HACE1, were found in HACE1-knockout mice as well as in patient cells, hypothesizing
that altered RAC1 signalling might contribute to the pathogenesis of the disorder [13,14]. The role
of RAC1 in the physiopathology of HACE1 deficiency is supported by the fact that this protein is
involved in brain development and in the regulation of reactive oxygen species (ROS) levels [6,15–17].
However, the fact that HACE1 has multiple substrates which participate in different fundamental
biological processes suggest that mechanisms other than RAC1 upregulation may also be to blame for
this disorder [18].
Here, we present a detailed study that provides further insight into elucidating the potential
pathomechanisms underlying HACE1 deficiency. We report a patient carrying HACE1 mutations
presenting with psychomotor retardation, brain atrophy and high urinary excretion of 3-methylglutaconic
acid (3-MGA), a well-established biomarker of mitochondrial dysfunction [19]. Molecular studies
revealed a severe defect in the regulation of the autophagic flux and a diminished ability to respond to
oxidative damage in HACE1 patient cells. The patient phenotype could resemble a mitochondrial defect
and the analysis of the mitochondrial function showed altered mitochondrial morphology and a partial
disassembly of the oxidative phosphorylation (OXPHOS) system. Notably, an important increase
in mitochondrial oxidative stress and a strong reduction in the mitophagic flux were demonstrated,
suggesting that the recycling of damaged mitochondria might be targeted in these cells. Altogether,
our results demonstrated that HACE1 mutations lead to a severe neurodevelopmental disorder by




We present the third child of healthy non-consanguineous parents of Pakistani origin. Pregnancy
and delivery were uneventful; the birth weight was 3500 g. During the first months of life, the patient
presented general psychomotor retardation without signs of regression. At the age of four years,
he achieved sedestation, but, currently, at 10 years of age, he is still not able to walk independently.
He has severe intellectual disability with greater impairment in the area of language. He displays
good connections with people by employing gestures to make him understood, although he only
uses familiar names and understands simple orders. Physical examination revealed paresis of the
lower extremities with rigidity and exalted osteotendinous reflexes with no other remarkable findings.
A brain magnetic resonance imaging (MRI) showed diffuse cortical atrophy and an arachnoid cyst
in the right temporal lobe. Routine biochemical analyses were normal, including amino acids and
acylcarnitines. The urinary organic acid profile showed persistently elevated levels of 3-metylglutaconic
and 3-methylglutaric acids, a biomarker associated to several mitochondrial diseases.
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2.2. Whole Exome Sequencing
Trio-exome enrichment and sequencing was performed in the Welcome Trust Sanger Institute.
Analysis of the primary data was done in the Centre Nacional d’Anàlisi Genòmica (CNAG) using
the RD-Connect Genome-Phenome Analysis Platform (GPAP) standardised analysis pipeline [20].
The variant calls were analyzed using the RD-Connect GPAP (https://platform.rd-connect.eu/).
2.3. Cell Culture
Human skin fibroblasts obtained from healthy donors and from a patient with mutations in
HACE1 were maintained in minimum essential medium (MEM) (1 g/L glucose, 10% fetal calf serum
and 1% penicillin-streptomycin). Cells were grown to confluence in 25 cm2 flasks, harvested by
trypsinization and pelleted by centrifugation or reseed.
2.4. Protein Expression Analysis
Cell pellets obtained from cultured fibroblasts were homogenized with RIPA buffer (SDS 0.1%,
NP40 1%, Sodyum deoxycholate 0.5% in PBS) containing protease inhibitors (cOmplete™, Mini,
EDTA-free Protease Inhibitor Cocktail 4693159001, Roche, Indianapolis, IN, USA). Cell lysates were
subjected to SDS-PAGE and electroblotted. Proteins were visualized by immunostaining with specific
antibodies (Table S1) followed by colorimetric detection (1708235 Opti-4CNTM Substrate Kit, Bio-Rad,
Hercules, California, USA). ImageJ software was used for densitometry analysis of protein expression.
Subcellular fractionation was performed in order to obtain total, cytoplasmatic and organelle-
enriched fractions. Cells were permeabilized with Lysis Buffer (5 mM Tris/HCl pH 7.4, 250 mM sucrose,
1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl2, 1 mM PMSF) containing 0.01% digitonin and centrifuged at
15000× g for 10 min at 4 ◦C. Supernatants (cytoplasmatic fraction) and pellets (membranous fraction)
were recovered and subjected to further analysis.
2.5. Blue Native-PAGE Analysis of Mitochondrial Complex and Supercomplex Assembly
Mitochondria-enriched pellets were obtained as described [21]. In order to extract mitochondrial
respiratory chain complexes, cells were homogenized with 1% n-dodecylβ-D-maltoside. For supercomplex
analysis, cells were solubilized with digitonin, a weaker detergent that maintains the interactions between
complexes. Lysates were electrophoresed in 4–15% polyacrylamide gradient gels, immunoblotted with
specific antibodies against representative subunits of the mitochondrial respiratory chain complexes I–V
(Table S1) and visualized by colorimetric detection (1708235 Opti-4CN™ Substrate Kit, Bio-Rad).
2.6. High-Resolution Respirometry
Oxygen consumption of control and HACE1 patient fibroblasts was analyzed by high resolution
respirometry using polarographic oxygen sensors in a two-chamber Oxygraph-2k system according
to manufacturer’s instructions (Oroboros Instruments, Innsbruck, Austria). Cells were trypsinised
and resuspended in MiR05 mitochondrial respiration medium (Oroboros Instruments, Innsbruck,
Austria). OXPHOS inhibitors (oligomycin, 04876-5MG, Sigma, St. Louis, MI, USA), antimycin,
A8674-25MG, Sigma, St. Louis, MI, USA) and uncoupler carbonyl cyanide 3-chlorophenylhydrazone
(CCCP, C2759,Sigma, St. Louis, MI, USA) were manually titrated using Hamilton syringes (Hamilton
Company, Reno, NV, USA) as previously described [22]. The concentrations used were 1 µg/mL of
oligomycin, stepwise 1 µM titration of CCCP and 2.5 µM of antimycin A. The data were recorded
using the DatLab software v7.1.0.21 (Oroboros Instruments, Innsbruck, Austria).
2.7. Mitochondrial Network and Mitochondria Morphology Analysis
The mitochondrial morphology and mitochondrial network were analysed by immunofluorescence
followed by confocal microscopy. Cells were grown on glass coverslips, fixed with 4% paraformaldehyde
and the reaction was stopped using NH4Cl. Fibroblasts were permeabilized with 0.1% TritonX-100 and
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mitochondria were stained using anti-TOM20 antibody (Table S1), which recognises a mitochondrial
membrane protein. Coverslips were mounted with Mowiol 4-88 Mounting Medium (81381 Sigma-Aldrich,
Sant Luis, MI, USA) and images were obtained using a Leica TCS SL laser scanning confocal spectral
microscope (Leica Microsystems GmbH, Wetzlar, Germany). Analysis was performed using ImageJ
software [23]. Mitochondrial length, the ratio between mitochondria length and width (aspect ratio, AR)
and the degree of mitochondrial network branching (form factor, FF) were calculated.
2.8. Analysis of Autophagy and Mitophagy in Fibroblasts
We assessed autophagy by analyzing LC3 protein by immunofluorescence and confocal microscopy.
Briefly, cells were grown on glass coverslips and fixed with 4% paraformaldehyde and permeabilized
using digitonin 100 µg/µL. In order to stain autophagosomes, a primary antibody anti-LC3 (Table S1)
was used. After mounting coverslips with Mowiol 4-88 Mounting Medium (81381, Sigma-Aldrich,
USA), images were obtained by Leica TCS SL laser scanning confocal spectral microscope (Leica
Microsystems GmbH, Wetzlar, Germany). Image analysis was done using ImageJ software and the
average number of LC3-II puncta (corresponding to autophagosomal LC-II form) was quantified.
In order to analyse the autophagic flux, LC3 puncta was analyzed in the presence and in the absence of
24 h EP (E64D-pepstatin A) treatment, two inhibitors of lysosomal hydrolases (10µM E64D (E8640,
Sigma Aldrich, St. Louis, MI, USA) and 10µM Pepstatin A (77170, Sigma Aldrich, St. Louis, MI, USA)).
Autophagic flux was determined as the relative increase in LC3-II puncta upon EP treatment compared
to those observed at the basal state.
Mitophagy was assessed by analyzing the colocalization between mitochondrial and LC3 areas,
as described [24]. Coverslips were prepared as described above. In this case, we determined the
colocalization areas using primary antibodies (Table S1) against LC3, staining autophagosomes, and
TOM20, staining the mitochondria. Mitophagy was calculated as the LC3-II/TOM20 colocalization
area related to the total mitochondrial area. To monitor the mitophagic flux, the ratio between
mitophagy upon EP treatment and without treatment was analysed. We measured the relative increase
in LC3-II/TOM20 colocalization areas upon 24 h of EP treatment compared to those detected in the
basal state.
To analyze autophagy induction, cells were subjected to nutrient starvation conditions by
exchanging the culture medium for Hank’s Balanced Salt solution (HBSS,14170-088, Gibco, Thermo
Fisher Scientific, Waltham, MA, USA) during 2 h. Autophagosome formation was assessed as mentioned
above. The nuclear translocation of the transcription factor EB TFEB (Table S1) was determined by
immunofluorescence as described [25]. Images were obtained using Eclipse 50 equipment (Nikon
instruments Inc., Melville, NY, USA) and the percentage of cells with nuclear TFEB was quantified for
each condition.
2.9. mRNA Expression Analysis
Total RNA extraction was performed using QIAshredder and RNeasy kits (74104 Qiagen, Hilden,
Germany). We synthesized single-stranded complementary DNA (cDNA) using oligodT primers
(C1101 Promega, Madison, WI, USA) and M-MLV Reverse Transcriptase, RNase H Minus, Point
Mutant (M368A Promega, Madison, WIS, USA) according to the manufacturer’s protocols. The levels
of mRNA expression were analysed by quantitative PCR using specific primers (Table S2). PCR was
performed using SYBR Green reagent (4472908, Life Technologies Ltd, Renfrew, UK) in a Step One plus
quantitative PCR system (Applied Biosystems, Waltham, MA, USA). In order to study the genes that
are upregulated under oxidative stress conditions, cells were treated with H2O2 (hydrogen peroxide
solution H1009, Sigma Aldrich, St. Louis, MI, USA).
2.10. Analysis of Mitochondrial Superoxide Levels
Mitochondrial superoxide levels were measured by MitoSOXRed probe (M36008, Invitrogene,
Waltham, MA, USA). Fibroblasts were seeded at 80% confluence. Experiments were performed
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following manufacturer’s indications, incubating cells with 5 µM MitoSOXRed for 10 min at 37 ◦C.
MitoSOXRed containing the medium was removed and cells were rinsed with Hank’s Balanced Salt
Solution with calcium and magnesium (HBSS/Ca/Mg, 14025-092, Gibco, Thermo Fisher Scientific,
Waltham, MA, USA). Fibroblasts were trypsinised and resuspended in HBSS/Ca/Mg. Fluorescence
intensity was analysed by flow cytometry (BD FACS CANTOTM II). Results are shown as the fold
increase in the average fluorescence intensity of each sample related to the controls.
2.11. Lipid Peroxidation Analysis
Lipid peroxidation levels were quantified using the BIOXYTECH® LPO-586™ colorimetric assay
(Oxys International Inc., Beverlly Hills, CA, USA). Specifically, the levels of malondialdehyde (MDA)
and 4-hydroxyalkenal (HAE), which are products of fatty acid peroxide decomposition, were analysed
by spectrophotometry. Results are expressed as (µM MDA + HAE)/mg protein.
2.12. Statistics
Statistical analyses were performed using the two-tailed Student’s t test to compare the means of
two independent groups of normally distributed data. The data were reported as the mean ± S.E.E.
Values of p < 0.05 were considered statistically significant.
3. Results
3.1. Identification of Mutations in HACE1
The clinical and biochemical phenotype of the patient reported here, in particular the persistently
high levels of 3-MGA in urine, set up a strong suspicion of a mitochondrial energy metabolism
disorder. However, mutations in all genes previously associated to 3-MGA-uria were ruled out using
a self-designed customized gene panel (Haloplex, Agilent Technologies, Santa Clara, CA, USA). In order
to elucidate the genetic cause of the disease, we performed whole-exome sequencing of the index case
and his healthy parents. Genetic variants were filtered and prioritized as summarized in Figure S1.
Data analysis revealed homozygous mutations in HACE1 (NM_020771.4). The identified mutation
(c.240C>A) is predicted to change the cysteine at position 80 of the protein for a translation termination
codon (p.Cys80Ter), leading to a potentially truncated protein. Segregation was confirmed by the
carrier status of both parents. HACE1 encodes for a HECT domain and ankyrin repeat-containing E3
ubiquitin ligase 1 protein, involved in tagging specific target proteins for subcellular localization or for
degradation [1].
3.2. HACE1 Protein Expression Is Absent in Patient Fibroblasts
To demonstrate the effect of the HACE1 mutations on the encoded protein, a Western Blot analysis
was performed. Results showed almost undetectable levels of HACE1 protein in patient fibroblasts, in
contrast to the abundant protein expression levels observed in control individuals (Figure 1A). These
results support the predicted disruptive effect of the mutation identified in our patient.
3.3. HACE1 Protein Is Mainly Expressed in Brain and Predominantly Localized in the Cytosolic Fraction
To investigate the physiological behavior of HACE1, we studied protein expression in a series of
human control tissues (total brain extracts, cortex (grey matter), periventricular (white matter), muscle,
heart, kidney, spleen and liver). Results showed that HACE1 was predominantly expressed in brain
tissues. Kidneys showed intermediate levels, whereas muscle, liver and spleen showed the lowest levels
(Figure 1B). As the patient phenotype was compatible with a mitochondrial disease, we performed
a fractionation analysis to determine the subcellular localization of HACE1 in control fibroblasts and
evaluate whether HACE1 could be associated to mitochondria. The results demonstrated that HACE1
protein is mainly located in the cytosolic fraction (Figure 1C).
J. Clin. Med. 2020, 9, 913 6 of 16
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 6 of 16 
 
 
Figure 1. HACE1 protein expression analysis in patient fibroblasts and human tissues. (A) Western 
Blot analysis showed almost absent expression of HACE1 in patient fibroblasts. Extracts from several 
controls (C1: control 1; C2: control 2 and C3: control 3) and two different extracts from the patient 
were analysed. Tubulin was used as the loading control. **p < 0.01. (B) Protein expression analysis in 
human control tissues showed a predominant HACE1 expression in brain samples. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as the loading control. (C) Fractionation studies 
performed in control fibroblasts showed that HACE1 is mainly localized in the cytoplasmic fraction. 
Protein markers of different organelles (mitochondria, endoplasmic reticulum (ER) and cytoplasm) 
were studied in order to corroborate proper fractionation. The ER marker (PDI) showed a cytosolic 
leakage, a phenomenon already observed for this marker [26–28]. T: total extract; C: cytoplasmic 
extract; M: membranous organelle-enriched fraction extract. 
3.4. Mitochondrial Function Characterization in HACE1 Patient Fibroblasts 
As the HACE1 patient reported here has a biochemical phenotype suggestive of a mitochondrial 
disorder, we performed an exhaustive characterization of the mitochondrial function. 
First, mitochondrial morphology and network branching were analysed by confocal 
microscopy. Results demonstrated a slight but statistically significant decrease in the parameters 
aspect ratio (AR) (indicative of morphology) and form factor (FF) (indicative of network branching) 
in HACE1 cells (p < 0.05). In addition, a significant reduction in the mitochondrial length was also 
observed in patient cells. These results suggest the presence of rounder and shorter mitochondria, as 
well as reduced network branching degree in HACE1 fibroblasts compared to controls (Figure 2A). 
We next assessed the impact of HACE1 deficiency in the OXPHOS system and mitochondrial 
respiratory capacity. The Blue Native PAGE analysis revealed a generalized decrease in fully 
assembled individual OXPHOS complexes in HACE1 patient cells (Figure 2B). Similar mitochondrial 
content was observed in patient and control cells, as demonstrated by the expression levels of TIM50 
(mitochondrial membrane protein) and ECHS1 (mitochondrial matrix protein) (Figure 2B, Figure S2). 
However, these defects had no impact in the assembly of the respirosome, since the levels of OXPHOS 
supercomplexes were not altered (Figure 2C). We then analysed the mitochondrial respiratory 
capacity by measuring the oxygen consumption rate (OCR) using high-resolution respirometry. 
Results showed no significant differences either in the basal respiratory rate or in the maximal 
respiratory capacity induced upon CCCP stimulation (Figure 2D, Figure S3). Unfortunately, due to 
material limitation and poor cell growth, a respirometry analysis to determine specific OXPHOS 
complex deficiencies could not be assessed. 
Figure 1. HACE1 protein expression analysis in patient fibroblasts and human tissues. (A) Western Blot
analysis showed almost absent expression of HACE1 in patient fibroblasts. Extracts from several controls
(C1: control 1; C2: control 2 and C3: control 3) and two different extracts from the patient were analysed.
Tubulin was used as the loading control. ** p < 0.01. (B) Protein expression analysis in human control
tissues showed a predominant HACE1 expression in brain samples. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the loading control. (C) Fractionation studies performed in
control fibroblasts showed that HACE1 is mainly localized in the cytoplasmic fraction. Protein markers
of different organelles (mitochondria, endoplasmic reticulum (ER) and cytoplas ) were studied in order
to corroborate proper fractionation. The ER marker (PDI) showed a cytosolic leakage, a phenomenon
already observed for this marker [26–28]. T: total extract; C: cytoplasmic extract; M: membranous
organelle-enriched fraction extract.
3.4. Mitochondrial Function Characterization in HACE1 Patient Fibroblasts
As the HACE1 patient reported here has a biochemical phenotype suggestive of a mitochondrial
disorder, we performed an exhaustive characterization of the mitochondrial function.
First, mitochondrial morphology and network branching were analysed by confocal microscopy.
Result demonstrated a slight bu statistically significant decrease in the paramet rs aspect ratio (AR)
(indicative of morphology) and form factor (FF) (indicative of netw rk branching) in HACE1 cells
(p < 0.05). In additi , a significant reductio in the mitochondrial length was lso observed in patient
cells. These results suggest the presence of rounder and shorter mitochondria, as well as reduced
network branching degree in HACE1 fibroblasts compared to controls (Figure 2A).
We next a sessed the impact of HACE1 deficiency in the OXPHOS system and mi ochondrial
respiratory capacity. The Blu Native PAGE analysis revealed a generalized ecreas in fully assembled
individual OXPHOS complexes in HACE1 patient cells (Figure 2B). Similar mito hondrial content was
observed in patient and control cells, as demonstrated by the expression levels of TIM50 ( it c
membrane protein) and ECHS1 (mitochondrial matrix protein) (Figure 2B, Figur S2). How ver, these
def cts had o impact in the assembly of the respirosome, si ce the levels of OXPHOS supercomplexes
were ot altered (Figure 2C). We then a alysed the mitochondrial respiratory capacity by measuring
the oxygen consumption rate (OCR) using high-resolution respirometry. Results show d no si nificant
differences either in the basal res iratory rate or in the maximal re piratory capacity induced upon
CCCP stimulation (Figure 2D, Figure S3). Unfortunat ly, due to material limitati n and poor c ll g owth,
a respirometry analysis to determi e specific OXPHOS complex deficiencies could not b assess d.
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Figure 2. Mitochondrial function in HACE1 fibroblast. (A) Mitochondria morphology analysis was 
performed by immunofluorescence using TOM20 antibody as mitochondrial marker. Results showed 
a significant reduction in AR (Aspect ratio, indicative of morphology) and FF (Form factor, indicative 
of mitochondrial network branching) in patient fibroblasts. A significant reduction in the 
mitochondrial length was also observed in patient cells. A minimum of 70 cells were analysed for 
each sample. Scale bar, 30 μm. *p < 0.05, ***p < 0.001. (B) Blue Native-PAGE studies and densitometry 
analysis of OXPHOS complexes showed a partial reduction in the assembly of all complexes in 
HACE1 patient fibroblasts. The expression of TIM50 (a mitochondrial membrane protein) and ECHS1 
(a mitochondrial matrix protein) were used as mitochondrial loading controls. (C) Blue Native-PAGE 
studies followed by densitometry analysis showed no alterations in the assembly of mitochondrial 
respiratory chain supercomplexes in HACE1 fibroblasts. (D) High resolution respirometry analysis 
showed no differences in the oxygen consumption rate between HACE1 and the control cells. Oxygen 
consumption rate at basal state (ROUTINE); residual oxygen consumption after oligomycin treatment 
(LEAK); maximum oxygen consumption induced by carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) titration (ETCmax); residual oxygen consumption after antimycin A treatment (ROX). 
Oxygen consumption rate (OCR) was measured as pmol/(second * millions of cells). The data is 
expressed as relative units (RU) of control cells. 
3.5. Autophagic Flux is Altered in HACE1 Patient Fibroblasts 
As HACE1 has been associated with the regulation of autophagy we have analyzed whether this 
process could be altered in HACE1 patient fibroblasts. Thus, we studied autophagy by 
immunofluorescence and confocal microscopy by measuring the average number of LC3 puncta per 
cell, indicative of autophagosomes harboring LC3-II (the lipidated and activated form of LC3). 
Results revealed that, in the basal state, HACE1 fibroblasts had a marked and significant increase in 
the number of LC3 puncta (four-fold, p < 0.001) compared to control cells (Figure 3A, left panel).  
The fact that autophagy is a highly dynamic process made the rationale for the analysis of the 
autophagic flux in these cells, in addition to the above-mentioned determination of steady state LC3-
II levels. Autophagic flux is defined as the process encompassing autophagosome formation to the 
delivery and degradation of autophagic substrates into the lysosome. To assess the autophagic flux, 
LC3 puncta was analyzed in the presence and in the absence of EP treatment, a strong inhibitor of 
the lysosomal hydrolases. This treatment blocks the degradation of autophagic substrates, including 
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si ific t r ction in R (Aspect ratio, indicative of morphology) and F (Form factor, indicative of
mitoch ndrial network branching) in patie t fibroblasts. A significant reductio in the mit cho drial
lengt was also observed in patient cells. A mi imum of 70 cells were analysed for each sample.
Scale bar, 30µm. * p < 0.05, *** p < 0.001. (B) Blue Native-PAGE studies and densitometry analysis of
OXPHOS complexes showed a partial reduction in the assembly of all complexes in HACE1 patient
fibroblasts. The expression of TIM50 (a mitochondrial membrane protein) and ECHS1 (a mitochondrial
matrix protein) were used as mitochondrial loading controls. (C) Blue Native-PAGE studies followed
by densitometry analysis showed no alterations in the assembly of mitochondrial respiratory chain
supercomplexes in HACE1 fibroblasts. (D) High resolution respirometry analysis showed no differences
in the oxygen consumption rate between HACE1 and the control cells. Oxygen consumption rate at basal
state (ROUTINE); residual oxygen consumption after oligomycin treatment (LEAK); maximum oxygen
consumption induced by carbonyl cyanide 3-chlorophenylhydrazone (CCCP) titration (ETCmax);
residual oxygen consumption after antimycin A treatment (ROX). Oxygen consumption rate (OCR)
was measured as pmol/(second * millions of cells). The data is expressed as relative units (RU) of
control cells.
3.5. Autophagic Flux Is Altered in HACE1 Patient Fibroblasts
As HACE1 has been associated with the regulation of autophagy we have analyzed whether
this process could be altered in HACE1 patient fibroblasts. Thus, we studied autophagy by
immunofluorescence and confocal microscopy by measuring the average number of LC3 puncta
per cell, indicative of autophagosomes harboring LC3-II (the lipidated and activated form of LC3).
Results revealed that, in the basal state, HACE1 fibroblasts had a marked and significant increase in
the number of LC3 puncta (four-fold, p < 0.001) compared to control cells (Figure 3A, left panel).
J. Clin. Med. 2020, 9, 913 8 of 16
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 16 
 
LC3-II, inside the autolysosome. Using this approach, we determined the amounts of LC3 particles 
which are delivered to lysosomes for degradation during EP treatment. As expected, our results 
showed that, upon EP treatment, the number of LC3-II puncta was significantly enhanced in both 
control and patient cells compared to their basal states (p < 0.001). Surprisingly, the fold increase in 
the number of LC3-II particles observed in HACE1 cells was lower (2.1-fold) than in control cells (7.9-
fold), regardless of the higher levels observed at the basal state. Therefore, the autophagic flux, 
defined as the relative increase in LC3-II after EP treatment compared to the basal levels observed in 
untreated cells, was markedly reduced in HACE1 fibroblasts (Figure 3A, right panel).  
To determine whether the alterations observed in HACE1 fibroblasts could rely on defects in the 
initial steps of the autophagic cascade, we monitored the formation of LC3-II puncta as well as the 
nuclear translocation of the transcription factor TFEB in cells treated with nutrient starvation, a well-
known autophagy inducer. Results showed a significant increase (p < 0.001) in the levels of LC3-II in 
controls as well as in HACE1 cells upon nutrient deprivation, indicating a rapid induction of 
autophagy (Figure 3B). In addition, control and HACE1 fibroblasts showed a similar capacity to 
translocate TFEB to the nucleus, as observed by the massive percentage of cells (89.7% and 83.7%, 
respectively) harbouring nuclear TFEB in response to serum starvation (Figure 3C). Interestingly, 
HACE1-mutated fibroblasts had an increased percentage of cells with nuclear TFEB at the basal state 
(31%) in comparison to that observed in controls (9.1%). Altogether, our results suggest that 
autophagy initiation, at least in response to nutrient deprivation stimuli, may not be significantly 
affected ue to HACE1 mutations. Moreover, the basal mRNA expression levels of autophagy genes 
(LC3, p62 and Beclin1) in patient cells were similar to those detected in controls (Figure S4). 
 
Figure 3. Autophagy analysis in HACE1 patient fibroblasts. Autophagy was measured by 
immunofluorescence measuring the average number of LC3 puncta per cell and the percentage of 
cells with TFEB translocated to the nucleus. (A) LC3 puncta was significantly increased in HACE1 
fibroblasts compared to control cells. The autophagic flux, calculated as the relative increase in 
LC3puncta after 24 hours of EP treatment compared to the basal levels observed in untreated cells, 
was importantly diminished in HACE1 fibroblasts. (B) Upon serum starvation treatment the number 
of LC3 puncta was increased in both, patient and control fibroblasts, indicating a normal activation 
of the autophagy. (C) The analysis of TFEB by immunofluorescence showed a massive translocation 
of TFEB to the nucleus after serum starvation treatment in both, control and HACE1 fibroblasts. In all 
cases a minimum of 70 cells were analysed. Scale bar, 30 μm. Relative units (RU); E64D-Pepstatine A 
(EP); *p < 0.05; **p < 0.01, ***p < 0.001. 
 
Figure 3. Autophagy analysis in HACE1 patient fibroblasts. Autophagy was measured by
immunofluorescence measuring the average number of LC3 puncta per cell and the percentage
of cells with TFEB translocated to the nucleus. (A) LC3 puncta was significantly increased in HACE1
fibroblasts compared to control cells. The autophagic flux, calculated as the relative increase in
LC3puncta after 24 h of EP treatment compared to the basal levels observed in untreated cells, was
importantly diminished in HACE1 fibroblasts. (B) Upon serum starvation treatment the number of
LC3 puncta was increased in both, patient and control fibroblasts, indicating a normal activation of the
autophagy. (C) The analysis of TFEB by immunofluorescence showed a massive translocation of TFEB
to the nucleus after serum starvation treatment in both, control and HACE1 fibroblasts. In all cases
a minimum of 70 cells were analysed. Scale bar, 30µm. Relative units (RU); E64D-Pepstatine A (EP);
* p < 0.05; ** p < 0.01, *** p < 0.001.
The fact that autophagy is a highly dynamic process made the rationale for the analysis of the
autophagic flux in these cells, in addition to the above-mentioned determination of steady state LC3-II
levels. Autophagic flux is defined as the process encompassing autophagosome formation to the
delivery and degradation of autophagic substrates into the lysosome. To assess the autophagic flux,
LC3 puncta was analyzed in the presence and in the absence of EP treatment, a strong inhibitor of
the lysosomal hydrolases. This treatment blocks the degradation of autophagic substrates, including
LC3-II, inside the autolysosome. Using this approach, we determined the amounts of LC3 particles
which are delivered to lysosomes for degradation during EP treatment. As expected, our results
showed that, upon EP treatment, the number of LC3-II puncta was significantly enhanced in both
control and patient cells compared to their basal states (p < 0.001). Surprisingly, the fold increase in the
number of LC3-II particles observed in HACE1 cells was lower (2.1-fold) than in control cells (7.9-fold),
regardless of the higher levels observed at the basal state. Therefore, the autophagic flux, defined as
the relative increase in LC3-II after EP treatment compared to the basal levels observed in untreated
cells, was markedly reduced in HACE1 fibroblasts (Figure 3A, right panel).
To determine whether the alterations observed in HACE1 fibroblasts could rely on defects in
the initial steps of the autophagic cascade, we monitored the formation of LC3-II puncta as well as
the nuclear translocation of the transcription factor TFEB in cells treated with nutrient starvation,
a well-known autophagy inducer. Results showed a significant increase (p < 0.001) in the levels of
LC3-II in controls as well as in HACE1 cells upon nutrient deprivation, indicating a rapid induction
of autophagy (Figure 3B). In addition, control and HACE1 fibroblasts showed a similar capacity to
translocate TFEB to the nucleus, as observed by the massive percentage of cells (89.7% and 83.7%,
respectively) harbouring nuclear TFEB in response to serum starvation (Figure 3C). Interestingly,
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HACE1-mutated fibroblasts had an increased percentage of cells with nuclear TFEB at the basal state
(31%) in comparison to that observed in controls (9.1%). Altogether, our results suggest that autophagy
initiation, at least in response to nutrient deprivation stimuli, may not be significantly affected due to
HACE1 mutations. Moreover, the basal mRNA expression levels of autophagy genes (LC3, p62 and
Beclin1) in patient cells were similar to those detected in controls (Figure S4).
3.6. Mitophagy Is Altered in HACE1 Fibroblasts
The suspicion of mitochondrial disorder together with the altered regulation of the autophagic flux
detected in patient fibroblasts prompted us to analyze if mitophagy could also be affected in HACE1
cells. Therefore, we evaluated mitophagy by analyzing the colocalization area of the mitochondria
(stained with an antibody against TOM20) and autophagosomes (stained with anti-LC3 antibody).
Results demonstrated a significantly increased (2.2-fold, p < 0.01) mitochondria–autophagosome
colocalization area in HACE1 fibroblasts, compared to controls (Figure 4, upper panel). To assess the
mitophagic flux we analyzed the colocalization in cells grown with and without EP (an inhibitor of
lysosomal degradation of the autophagosomal content). As expected, in control cells, the colocalization
area was significantly enhanced upon EP treatment (4.2-fold, p < 0.01). In contrast, in HACE1 fibroblasts
the effect of EP treatment was milder, resulting in a moderate increase (1.4-fold) of the colocalization
respect to the basal situation (Figure 4, upper panel). The mitophagic flux was determined as the
relative increase in the mitochondria–autophagosome colocalization area upon EP treatment compared
to the basal colocalization. Results demonstrated that, in comparison to controls, the mitophagic flux
was markedly reduced in HACE1 fibroblasts (Figure 4, lower panel).
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Figure 4. Mitophagy analysis in HACE1 patient fibroblasts. Mitophagv was assessed by
immunofluorescence measuring the mitochondria–autophagosome colocalization. Mitochondria was
stained with anti-TOM20 and autophagosomes with anti-LC3 antibody. Colocalization was significantly
increased in HACE1 fibroblasts compared to control cells. The mitophagic flux, determined as the
relative increase in the colocalization area observed after 24 h of EP treatment compared to the basal
colocalization, was markedly reduced in HACE1 fibroblasts. In all conditions a minimum of 70 cells
were analyzed. Scale bar, 30µm. Relative units (RU); E64D-Pepstatine A (EP); * p < 0.05; ** p < 0.01,
*** p < 0.001.
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3.7. HACE1-Mutated Fibroblasts Accumulate Oxidative Damage and Have a Diminished Ability to Respond to
Oxidative Stress
Cellular and animal models propose a role for HACE1 in oxidative stress response. To determine
whether HACE1 deficiency could lead to oxidative damage, we analyzed lipid peroxidation in the
HACE1 patient and control fibroblasts. Lipid peroxidation is one of the consequences derived from
the accumulation of high levels of cellular ROS. Therefore, we studied the levels of malondialdehyde
and 4-hydroxialkenal content and demonstrated a significant increase (p < 0.05) in both products
in HACE1 mutant cells (Figure 5A). These results were indicative of accumulated cellular oxidative
damage and raised the question whether the response to oxidative stress could also be impaired in
HACE1 fibroblasts and, in consequence, involved in the physiopathology of the disease. To this effect,
we analyzed the mRNA expression levels of NQO1 and HMOX1, two well-known genes reported to
be upregulated in response to oxidative stress. Interestingly, our results showed that the basal mRNA
levels of both genes were significantly decreased in the patient’s fibroblasts (p < 0.01). Furthermore,
upon H2O2-induced oxidative stress the induction of NQO1 and HMOX1 mRNA expression was also
strongly diminished in HACE1-mutated cells (Figure 5B).
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Figure 5. Analysis of oxidative stress in HACE1 patient fibroblasts. (A) The quantification of
malondialdehyde and hydroxialkenal levels demonstrated higher levels of lipid peroxidation in HACE1
patient fibroblasts. P, patient; C1-C3, controls. * p < 0.05. (B) Quantitative PCR showed significantly
decreased mRNA levels of HMOX1 and NQO1 at the basal state as well as upon oxidative stress induced
by H2O2 in HACE1 patient. Experiments were performed in triplicate and results are expressed in
relative units (RU). Peptidylprolyl isomerase A (PPIA) was used as an internal control. * p < 0.05,
** p < 0.01, *** p < 0.001. (C) Mitochondrial superoxide anion levels were analyzed by MitoSOXRed
staining and flow cytometry. Increased levels of MitoSOXRed fluorescence intensity were detected in
HACE1 patient fibroblasts. Cells treated with antimycin A were used as positive control. Results are
expressed in relative units (RU). Patient (P); control (C); positive control (C+); * p < 0.05. (D) Western
Blot analysis demonstrated higher levels of SOD2 protein expression in HACE1 patient fibroblasts.
GAPDH was used as the loading control. Cell lysates from several controls (C) and four different
extracts from the patient (P) were analyzed. * p < 0.05.
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3.8. HACE1 Fibroblasts Had Increased Mitochondrial Oxidative Stress
In order to specifically analyze the presence of mitochondrial oxidative stress, we determined
the levels of superoxide anion (the main mitochondrial ROS) in living cells by flow cytometry using
a MitoSOXRed probe. Control fibroblasts treated with antimycin, which severely impairs mitochondrial
respiratory chain activity and leads to ROS accumulation, were used as a positive control. As expected,
antimycin treatment resulted in a significant increase (3.9-fold, p < 0.001) in MitoSOXRed intensity
compared to untreated cells (Figure 5C). Interestingly, HACE1 fibroblasts showed a significant increase
(2.2-fold, p < 0.05) in the basal levels of mitochondrial superoxide anion compared to the controls
(Figure 5C). In addition, the levels of the mitochondrial antioxidant dismutase enzyme SOD2 analyzed
by Western Blot were also increased in HACE1 fibroblasts (p < 0.05). Altogether, these results indicate
enhanced mitochondrial oxidative stress in HACE1-mutated cells (Figure 5D).
4. Discussion
In the last decade, the implementation of next generation sequencing technologies has allowed
the identification of an increasing number of disease-causing variants in genes associated to a wide
variety of cellular processes [29]. However, the physiopathological bases of most rare genetic disorders
are yet to be completely elucidated. Here, we report on a patient with psychomotor retardation,
brain atrophy and 3-MGA-uria carrying a previously reported homozygous mutation (c.240C>A;
p.Cys80Ter) in HACE1, which encodes for a HECT domain and ankyrin repeat-containing ubiquitin
ligase protein [10]. The identified mutation was predicted to generate a premature termination codon
at residue 80; therefore, the disruptive effect was demonstrated by Western Blot, as HACE1 protein
expression levels were absent in patient fibroblasts. HACE1 plays an important role in tagging specific
proteins for subcellular localization or proteasomal degradation [1] and, as confirmed here by Western
Blot analysis, it is mainly expressed in brain tissues [13,30,31].
To date HACE1 bi-allelic mutations have been reported in eight unrelated families [10–13].
The clinical data of the previously described individuals do not differ from the phenotype of the patient
reported here, but 3-MGA-uria has not been reported in any of the previous cases. Although the true
origin of 3-MGA excretion is not well known, the presence of this metabolite in urine is considered
a good biomarker of mitochondrial dysfunction; in particular, it has been associated to mutations in
genes encoding for proteins related to the mitochondrial membrane [19,32]. Even though the patient
phenotype could resemble a mitochondrial disorder, a subcellular fractionation analysis performed in
control fibroblasts demonstrated that HACE1 mainly localizes in the cytosolic fraction. These results
are concordant with previous observations made in NIH3T3 murine cells, which showed that HACE1
was barely expressed in the mitochondria but cofractionate with cytosolic and endoplasmatic reticulum
markers [30]. Since 3-MGA-uria is frequently associated to alterations of the mitochondrial morphology
and the assembly of the OXPHOS system [19,32], we performed a detailed analysis of the mitochondrial
function in HACE1 mutated cells. The results showed alterations in the mitochondrial morphology
and a partial disassembly of the OXPHOS system. However, these alterations have no impact on the
formation of the mitochondrial respiratory supercomplexes or in the cellular respiratory capacity.
Although mutations in HACE1 have already been reported, the physiopathological mechanisms
underlying this disorder are not yet fully understood. To this regard, a very recent publication provided
the first and, so far, most unique insight into the molecular consequences of HACE1 deficiency in
human disease [13]. The authors demonstrated that RAC1, a well-known HACE1 target associated to
brain development and regulation of intracellular ROS, is importantly upregulated in HACE1 patient
cells. Indeed, ROS levels were also increased in these cells, pointing that altered RAC1 signalling
might contribute to the pathogenesis of the disorder. However, it has been postulated that RAC1
upregulation would not explain the whole phenotypic spectrum of this disease, suggesting that
other molecular pathways might also be involved [18]. Interestingly, several studies performed in
different organisms and cellular models have implicated HACE1 in the regulation of other fundamental
cellular processes, including autophagy [7,8], activation of antioxidant response and cell survival upon
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oxidative damage [4,5]. In the present study, we wondered whether these pathways could also be
impaired in HACE1 patient fibroblasts and contribute to the physiopathology of the disease.
Autophagy is an evolutionarily conserved process that recycles cellular components and organelles
by targeting intracytoplasmic cargo to lysosomes for degradation [33–36]. In addition to lysosomes,
the proper function of this process requires the formation of autophagosomes, highly specialized
double-membraned organelles that enclose a portion of cytoplasmatic material for further fusion
and delivery to lysosomes. In the present study, we have analyzed autophagy by evaluating LC3
protein. LC3 is localized in the cytosol (LC3-I form) until it becomes activated and re-localized to
the autophagosome membranes (LC3-II form). Autophagosomes can be detected and quantified
by immunofluorescence as bright LC3 positive puncta [37]. Using this approach, we demonstrated
a pronounced increase in LC3 puncta in patient fibroblasts when compared to control cells. These
results indicate that, in the basal state, autophagosomes are abnormally accumulated in HACE1
mutated cells. However, since autophagy is a dynamic process, the accumulation of LC3 particles can
be promoted either by autophagy activation or by a blockade of downstream stages. In fact, the basal
number of autophagosomes is the balance between the rate of autophagosome formation and the rate
of autophagosome fusion with the lysosomes and the subsequent degradation of their content [34].
Interestingly, the mRNA levels of LC3 as well as other autophagy regulators, such as p62 and Beclin 1,
were not increased in HACE1 mutated cells. These observations suggested that the higher number of
LC3 puncta observed in patient fibroblasts might be due to post transcriptional regulatory mechanisms
rather than an induction of autophagy via the activation of mRNA transcription. Moreover, autophagy
initiation seemed to be unaltered in HACE1-deficient cells since nutrient deprivation treatment,
a well-known and potent autophagy inducer, provoked a massive nuclear translocation of TFEB and
a rapid generation of autophagomes in both patient and control fibroblasts [25,34]. We next measured
the autophagic flux by analyzing the LC3-II turnover, treating the cells with EP, a strong inhibitor
of the lysosomal hydrolases that allows autolysosome formation but blocks the degradation of the
autolysosomal content [38]. We demonstrated that the autophagic flux, calculated as the relative
increase in LC3-II levels observed upon EP treatment compared to those in the basal state, was strongly
decreased in the HACE1 patient’s fibroblasts. Our results are consistent with the reported observations
that showed an abnormal accumulation of LC3 protein in HACE1-knockout mice and also demonstrate
that HACE1 is involved in the late stages of the autophagosome maturation process [7]. These
observations, along with the new data reported here, suggest that the reduced autophagic flux detected
in the HACE1 patient might be due to delayed completion of the autophagy pathway. Our results
provide the first evidence of impaired autophagy in HACE1 patients and propose the involvement of
this mechanism in the physiopathology of the disease.
Several studies performed in mice and cell models proposed a role for HACE1 in the regulation of
the oxidative stress response [4–6]. The principal consequence of a poor management of cellular redox
disturbances is the increase in ROS levels, which react with and damage cellular components such as
proteins, lipids and DNA [39–41]. Here, we demonstrated an abnormal accumulation of ROS-derived
cellular damage in HACE1 mutated fibroblasts, as seen by increased lipid peroxidation. In addition to
RAC1 regulation, HACE1 is also involved in ROS detoxification by promoting the stability of the nuclear
factor erythroid 2-related factor 2 (NRF2), a master regulator of the antioxidative response [4,5,42].
Under oxidative stress conditions NRF2 transcription factor translocates to the nucleus and induces the
expression of a plethora of genes involved in the response to oxidative damage [43–45]. Indeed, it has
been shown that, upon oxidative stress, the proper induction of NRF2 target genes is severely impaired
in cells derived from HACE1 knockout mice [4,5]. Notably, we demonstrated that in HACE1 patient
fibroblasts, the mRNA levels of NQO1 and HMOX1, two NRF2 transcriptional targets, reported to be
upregulated in response to oxidative stress, were significantly reduced even upon H2O2 treatment.
These results suggest that the accumulation of oxidative damage in HACE1 fibroblasts could rely,
at least in part, on the diminished ability of these cells to respond to oxidative stress via NRF2. Our data
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provide further evidence supporting the role of oxidative damage in the pathogenesis of HACE1
deficiency and complement the recently reported observations made by Nagy et al. (2019) [13].
As discussed above, the phenotype of the HACE1 patient reported here resembles a mitochondrial
disorder. Mitochondria are the major source of intracellular ROS, where incomplete reduction of
oxygen or electron leakage from the mitochondrial respiratory chain generates superoxide radical
anions [39–41]. The fact that oxidative damage is importantly accumulated in HACE1 fibroblasts
prompted us to specifically analyze mitochondrial ROS in these cells. Increased levels of superoxide
radical anions and high SOD2 expression evidenced that mitochondrial oxidative stress was also
present in HACE1 mutated cells. These observations could be controversial since it has been reported
that SOD2 is also a target of NRF2. Nevertheless, the oxidative damage response pathways are complex
and involve a large number of proteins and transcription factors. Therefore, the high levels of SOD2
detected in HACE1-deficient cells could be due to the action of factors other than NRF2, such as PGC-1α,
a master co-regulator of energy metabolism, SIRT3, among others [40]. These observations together
with the persistently high levels of 3-MGA-uria and slight mitochondrial morphology alterations made
the rationale to determine whether mitophagy, the selective form of autophagy that recycles damaged
mitochondria, could also be targeted [46]. Mitophagy was determined by immunofluorescence,
measuring the mitochondria–autophagosome colocalization area [24]. Similar to the results observed
for general autophagy, the mitophagic flux was strongly decreased in patient cells, concluding that
the turnover of damaged mitochondrial was also impaired as a consequence of HACE1 mutations.
However, future experiments using more sophisticated analysis methods [47,48] will be required in
order to obtain quantitative mitophagy data and to improve the knowledge of the defects caused by
HACE1 deficiency.
5. Conclusions
In summary, the present study, together with the recently reported observations of Nagy et al.
(2019) [13], represents the first characterization of the molecular mechanisms underlying HACE1
deficiency in human disease. Here, we demonstrated that HACE1 mutations lead to a severe
impairment of the autophagic flux and a decreased ability to respond to oxidative damage. In addition,
we also showed increased mitochondrial oxidative stress and altered mitophagy in HACE1 patient
cells. Altogether, our observations suggest, for the first time, that these physiological processes
may be involved in the pathogenesis of this disorder. However, future studies based on functional
complementation of HACE1 patients’ fibroblasts and the analysis of HACE1-deficient neuronal cell
lines will be required to gain further knowledge about the contribution of altered autophagy, mitophagy
and oxidative stress impairment in the physiopathology of this disorder.
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